EIZO (6737) Q2 2027 earnings summary

Executive summary

• H1 FY2027 net sales rose 7.5% YoY to ¥40.697bn, led by V&S growth and solid Healthcare sales; favorable EUR movements also supported results.

• Operating profit increased to ¥1.815bn; net income reached ¥4.938bn, including a ¥4.464bn gain on sale of investment securities.

• FY2027–FY2029 begins a three-year transformation and profit-structure reform agenda, focusing on growth areas and integrated imaging solutions through EVS.

Financial highlights

• Gross profit rose 12.9% YoY to ¥13.944bn; gross margin expanded 1.7 percentage points to 34.3%.

• Operating profit was ¥1.815bn versus ¥659m; ordinary profit rose 64.3% to ¥2.451bn.

• Profit attributable to owners rose 430.7% to ¥4.938bn, including a ¥4.464bn securities-sale gain.

• SG&A increased 3.8% to ¥12.129bn; European cost reductions and lower technology-hub expenses were partly offset by FX effects on overseas costs.

• Comprehensive income was ¥38.687bn, including ¥34.358bn of available-for-sale securities valuation gains in other comprehensive income.

Outlook and guidance

• FY2027 guidance remains unchanged: net sales ¥85.0bn, operating profit ¥3.3bn, ordinary profit ¥4.6bn, net income ¥6.5bn and EPS ¥167.60.

• Guidance was maintained despite performance above expectations because of component procurement uncertainty; revisions may follow as conditions evolve.

• FY2027 annual dividend forecast is ¥115 per share, including a ¥57.50 second-quarter dividend; no revision was made.